Events

Metastatic Colorectal Cancer World Day

21 September 2022

Knowing your biomarker can make the difference. 

Ask your healthcare team to learn more

 

Image
mCRC world day Pierre Fabre

 

 

Why is it important to know CRC tumour biomarkers?

Every colorectal cancer is unique. 
Knowing its characteristics is like having the ID card of the tumour. When we look for tumour molecular characterization, it is called molecular testing.
The type of colorectal cancer influences, among other things, the following:
- Prognosis (the estimated course of the cancer)
- Treatment options available (which can vary depending on tumour type)
Biomarkers and molecular testing are becoming increasingly important. In addition to their prognostic value, some of them also have a predictive value for the effectiveness of some treatments 1.

When should metastatic colorectal cancer patients be tested for biomarker

Image
biomarkers profiles

For most patients diagnosed with metastatic colorectal cancer (stage IV), biomarker testing is recommended before starting any therapy to choose the best treatment strategy. As recommended by ESMO guidelines, RAS, BRAF and MSI-H/dMMR status should be known2.

 

You want to learn more about biomarker testing?

  1. Ask your healthcare team
  2. Ask your local patient organization
  3. You can also consult dedicated material and contents made by, with and for patients:

 

CRC facts and figures

Approximately
0 million
cases are diagnosed annually, of which approximately 520,000 are diagnosed in Europe.3
Globally, the prevalence of CRC is expected to rise to more than
0 millions
cases per year by 2040.4
Colorectal cancer (CRC) is the third most common cancer in the world,3 with
0 in 4
people diagnosed when the disease has already metastasised (stage IV). 5

Want to learn more about Pierre Fabre and our commitment to colorectal cancer patient community? Check our dedicated webpage: Finding ways that work for you: raising awareness about reducing the risk of colorectal cancer during Blue March ! (www.pierre-fabre.com)

 

References:

  1. Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol. 2020;17(1):11-32. doi:10.1038/s41571-019-0241-1 https://pubmed.ncbi.nlm.nih.gov/31289352/
  2. Van Cutsem E, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016;27:1386–422. Annals of Oncology 27: 1386–1422, 2016 doi:10.1093/annonc/mdw235 Available at : https://www.annalsofoncology.org/article/S0923-7534(19)34754-4/fulltext
  3. The Global Cancer Observatory, 2020. International Agency for Research on Cancer, World Health Organization. Available at: https://gco.iarc.fr/today/data/factsheets/cancers/10_8_9-Colorectum-fact-sheet.pdf
  4. Gunter MJ, et al. Ann Oncol. 2019;doi: 10.1093/annonc/mdz044. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6503626/pdf/mdz044.pdf 
  5. American Cancer Society. Colorectal Cancer Facts and Figures 2020-2022. Available at: https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/colorectal-cancer-facts-and-figures/colorectal-cancer-facts-and-figures-2020-2022.pdf (accessed January 2022)

HQ--08-22-2200015